Neuren Defends Timely Disclosure of Material DAYBUE Sales Projections to ASX

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an announcement.

Neuren Pharmaceuticals has confirmed to the ASX that recent information disclosed by its partner Acadia Pharmaceuticals on projected DAYBUE net sales, including a substantial increase in expected 2028 revenue versus 2025 guidance, is materially important for Neuren’s share price because royalties and milestones from DAYBUE are its only current source of product income. The company detailed the timeline of when it became aware of Acadia’s updated projections, outlined how it complied with continuous disclosure obligations by rapidly reviewing Acadia’s announcements, analyst forecasts and internal models before releasing its own market update, and asserted it has reasonable grounds to reference a projection of approximately US$700 million in global DAYBUE sales in 2028, relying on Acadia’s regulated disclosures in the US.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$23.50 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company that derives its current product revenue solely from royalties and milestone payments linked to global sales of DAYBUE, a therapy it has licensed exclusively worldwide to US-based Acadia Pharmaceuticals. Under this arrangement, Acadia is fully responsible for the development and commercialisation of DAYBUE, which was approved and launched in the United States in 2023, while Neuren’s financial performance is directly tied to Acadia’s net sales guidance and commercial execution for the product.

YTD Price Performance: 2.85%

Average Trading Volume: 341,117

Technical Sentiment Signal: Buy

Current Market Cap: A$2.42B

See more data about NEU stock on TipRanks’ Stock Analysis page.